

NCT02748330 Raw comparison:

Summary:
CHIA has 14 criteria while your personal folder has 43 criteria
Total found criteria: 13/14
Total not Found: 1/14
Total Extra: 29
This trial is INVALID



╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╕
│ CHIA Criteria                                      │ Matching Personal Criteria                         │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╡
│ Provision of written informed consent (by patient  │ Provision of written informed consent (by patient  │
│ or appropriate designee according to local         │ or appropriate designee according to local         │
│ regulations) prior to any study specific           │ regulations) prior to any study specific           │
│ procedures                                         │ procedures                                         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Aged 18 years or older male or female              │ Aged 18 years or older male or female              │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ History of stable angina pectoris with             │ History of stable angina pectoris with             │
│ angiographic evidence of CAD (diameter stenosis =  │ angiographic evidence of CAD (diameter stenosis ≥  │
│ 50%) in major i e left main left anterior          │ 50%) in major i e left main left anterior          │
│ descending left circumflex and right coronary      │ descending left circumflex and right coronary      │
│ arteries                                           │ arteries                                           │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ History of previous myocardial infarction (MI)     │ History of previous myocardial infarction (MI)     │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ History of coronary revascularization i e          │ History of coronary revascularization i e          │
│ percutaneous coronary intervention (PCI) or        │ percutaneous coronary intervention (PCI) or        │
│ coronary artery bypass graft (CABG) not including  │ coronary artery bypass graft (CABG) not including  │
│ the elective PCI during the index hospitalization  │ the elective PCI during the index hospitalization  │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Documented history of type 2 diabetes mellitus     │ Documented history of type 2 diabetes mellitus     │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Post-procedural residual diameter stenosis of the  │ Post-procedural residual diameter stenosis of the  │
│ treated lesions < 20% in patients with stent       │ treated lesions \< 20% in patients with stent      │
│ implantation or < 50% in those with balloon        │ implantation or \< 50% in those with balloon       │
│ angioplasty                                        │ angioplasty                                        │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Post-procedural thrombolysis in myocardial         │ Post-procedural thrombolysis in myocardial         │
│ infarction (TIMI) grade 3 flow in treated vessels  │ infarction (TIMI) grade 3 flow in treated vessels  │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Negative cardiac troponin test before the index    │ Negative cardiac troponin test before the index    │
│ elective PCI                                       │ elective PCI                                       │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Taking Clopidogrel 75 mg daily dose for at least 7 │ Taking Clopidogrel 75 mg daily dose for at least 7 │
│ days or taking Clopidogrel 75 mg daily dose for    │ days or taking Clopidogrel 75 mg daily dose for    │
│ less than 7 days but with 300 to 600 mg            │ less than 7 days but with 300 to 600 mg            │
│ Clopidogrel loading dose before PCI                │ Clopidogrel loading dose before PCI                │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Taking acetylsalicylic acid (ASA) 100 mg daily     │ Taking acetylsalicylic acid (ASA) 100 mg daily     │
│ treatment for at least 7 days or taking ASA 100 mg │ treatment for at least 7 days or taking ASA 100 mg │
│ daily dose for less than 7 days but with 300 mg    │ daily dose for less than 7 days but with 300 mg    │
│ ASA loading dose before PCI                        │ ASA loading dose before PCI                        │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ have a negative urine or blood pregnancy test at   │ have a negative urine or blood pregnancy test at   │
│ enrolment and prior to randomization               │ enrolment and prior to randomization               │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ currently be using a hormonal contraceptive and    │ currently be using a hormonal contraceptive and    │
│ agree to continue its use in addition to using     │ agree to continue its use in addition to using     │
│ double-barrier local contraception (i e intra-     │ double-barrier local contraception (i e intra-     │
│ uterine device plus spermicidal and condom for     │ uterine device plus spermicidal and condom for     │
│ male partner) from screening through study         │ male partner) from screening through study         │
│ completion                                         │ completion                                         │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╛



╒═══════════════════════════════════════╕
│ CHIA Criteria Not Found in Personal   │
╞═══════════════════════════════════════╡
│ NA                                    │
╘═══════════════════════════════════════╛



╒═════════════════════════════════════════════════════════════════════════════════════════════════════╕
│ Extra Personal Criteria                                                                             │
╞═════════════════════════════════════════════════════════════════════════════════════════════════════╡
│ Involvement in the planning and conduct of the study (applies to investigators contract research    │
│ organization staff and study site staff)                                                            │
├─────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ History of intolerance to ASA Clopidogrel or Ticagrelor                                             │
├─────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Contraindication or other reason that ASA Clopidogrel or Ticagrelor should not be administered (e g │
│ hypersensitivity active bleeding \[including active pathological bleeding\] any bleeding tendency   │
│ \[coagulation defects\] moderate and severe hepatic impairment risk of bradycardia chronic          │
│ obstructive pulmonary disease chronic or active asthma hyperuricemia gout etc )                     │
├─────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Increased bleeding risk including                                                                   │
├─────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Concomitant therapy with moderate or strong cytochrome P-450 (CYP) 3A inhibitors CYP 3A substrates  │
│ with narrow therapeutic index or strong CYP 3A inducers during study period                         │
├─────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ At least 24 hours after but within 14 days of angiographically successful elective PCI without      │
│ complications                                                                                       │
├─────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Occurrence of myocardial infarction (MI) related to index elective PCI (type 4a MI) or myocardial   │
│ infarction related to stent thrombosis (type 4b MI) according to the Third Universal Definition of  │
│ Myocardial Infarction                                                                               │
├─────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ sustained uncontrolled hypertension (systolic blood pressure \[SBP\] \> 180 mmHg or diastolic blood │
│ pressure \[DBP\] \> 100 mmHg)                                                                       │
├─────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Patients who had acute coronary syndrome (ACS) within 12 months of screening                        │
├─────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Recent (within 30 days of screening) blood donation                                                 │
├─────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ history of hemorrhagic disorders that can increase the risk of bleeding e g haemophilia von         │
│ Willebrand's disease                                                                                │
├─────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ History of drug addiction or alcohol abuse in the previous 2 years                                  │
├─────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Participation in another investigational drug or device study within 30 days of screening           │
├─────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ recent (within 30 days of screening) gastrointestinal (GI) bleeding                                 │
├─────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Use of any oral antithrombotic agents with the exception of Clopidogrel and ASA within 30 days of   │
│ screening                                                                                           │
├─────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Concomitant therapy with moderate or strong CYP 2C19 inhibitors CYP 2C19 substrates with narrow     │
│ therapeutic index or strong CYP 2C19 inducers during study period                                   │
├─────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Any other indications (e g atrial fibrillation prosthetic heart valve venous thromboembolism        │
│ ventricular thrombosis et al) for antithrombotic treatment other than ASA 100 mg daily Clopidogrel  │
│ and Ticagrelor during study period                                                                  │
├─────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Patient requires dialysis or has a creatinine clearance (Clcr) \< 30 mL/min as calculated by the    │
│ Cockcroft-Gault equation Clcr = (140 - Age) × WT / (72 × Scr) (× 0 85 for females) where WT is      │
│ weight in kg Scr is serum creatinine in mg/dL                                                       │
├─────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ recent (within 30 days of screening) major trauma or major surgery                                  │
├─────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Use of parenteral antithrombotic agents e g glycoprotein IIb/IIIa inhibitors (GPIs) bivalirudin     │
│ unfractionated heparin enoxaparin or fondaparinux within 24 hours of screening                      │
├─────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Females with childbearing potential (i e females who are not post-menopausal or surgically sterile) │
│ must                                                                                                │
├─────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ any history of intracranial intraocular retroperitoneal or spinal bleeding                          │
├─────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Patients that are scheduled for CABG during the study period                                        │
├─────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Known pregnancy breast-feeding or intend to become pregnant during the study period                 │
├─────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ inability to discontinue required concomitant therapy with non-selective non-steroidal anti-        │
│ inflammatory drugs (NSAIDs) at screening                                                            │
├─────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Any acute or chronic unstable conditions in the past 30 days or other conditions which in the       │
│ opinion of the investigator may either put the patient at risk or influence the result of the study │
│ (e g active cancer risk for non-compliance risk for being lost to follow-up)                        │
├─────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ platelet count less than 100 000/mm3 or hemoglobin \< 10 g/dL                                       │
├─────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Documented stable coronary artery disease (CAD) fulfilling any of the following                     │
├─────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Must have minimum age of 18 Years                                                                   │
╘═════════════════════════════════════════════════════════════════════════════════════════════════════╛